EUVIMEDScopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

hERG1 channels and potential therapeutics for long QT syndrome

Elizabeth H Schneider, Kelly A Aromolaran, Michael C Sanguinetti, Ademuyiwa S Aromolaran

The Journal of Physiology · 2026-07-01

DOI: 10.1113/jp291452 ↗

At a glance

Übersichtsarbeit in The Journal of Physiology, published online on 2026-07-01. Written by Elizabeth H Schneider and 3 co-authors. Institution: Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, Utah, USA. Cited 1 times so far (Crossref); 105 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHLBI NIH HHS, Nora Eccles Harrison Treadwell Foundation, National Heart, Lung, and Blood Institute.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The human ether‐à‐go‐go‐related gene type 1 (hERG1) channel is a voltage‐gated potassium channel encoded by the KCNH2 gene. hERG1 channels are essential to the repolarization of cardiac action potentials, and reduced function of the potassium current conducted by hERG1 channels ( I Kr ) is pathogenic, leading to type 2 long QT syndrome (LQT2). LQT2 results from congenital mutation(s) of KCNH2 and affects approximately 1 in 6000 people. A mutation‐induced decrease in I Kr can be caused by altered channel gating but is most often caused by misfolding and early degradation of hERG1 protein, resulting in reduced trafficking of channels to the plasma membrane. Prolongation of the QT interval can also be drug induced, and many drugs fail preclinical safety assessments due to their inhibition of hERG1 channels. In this review we assess the molecular and structural bases of hERG1 channel function. Furthermore we examine the pharmacology of hERG1 inhibitors and hERG1 channel trafficking mediators, the pathogenesis of LQT2 that can be triggered through these mechanisms and translational and clinical perspectives that may be useful in the prevention and treatment of LQT2. By understanding the molecular mechanisms that lead to the pathophysiological development of LQT2 new therapeutics can be developed to treat this disorder. image

Subjects

Author keywords

KV11.1arrhythmiaion channel gatingion channel traffickinglong QT syndrome

Authors and institutions

  • Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Department of Internal Medicine, Division of Cardiovascular Medicine, University of Utah, Salt Lake City, Utah, USA.
  • Department of Surgery, Division of Cardiothoracic Surgery, Biochemistry, Nutrition & Integrative Physiology, Biomedical Engineering & Molecular Medicine Program, University of Utah School of Medicine, Salt Lake City, Ut…

Funding

  • NHLBI NIH HHS
  • Nora Eccles Harrison Treadwell Foundation
  • National Heart, Lung, and Blood Institute

Cite

APA

Schneider, E. H., Aromolaran, K. A., Sanguinetti, M. C., & Aromolaran, A. S. (2026). hERG1 channels and potential therapeutics for long QT syndrome. The Journal of Physiology. https://doi.org/10.1113/jp291452

Vancouver

Schneider EH, Aromolaran KA, Sanguinetti MC, Aromolaran AS. hERG1 channels and potential therapeutics for long QT syndrome. The Journal of Physiology. 2026. doi:10.1113/jp291452

BibTeX
@article{Schneider2026,
  author = {Schneider, Elizabeth H and Aromolaran, Kelly A and Sanguinetti, Michael C and Aromolaran, Ademuyiwa S},
  title = {hERG1 channels and potential therapeutics for long QT syndrome},
  journal = {The Journal of Physiology},
  year = {2026},
  doi = {10.1113/jp291452}
}
Start for free →